-
421
Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
Published 2025-01-01“…Methods This retrospective study included 57 patients with NSCLC (52 men and 5 women), aged ≥ 75 years (range: 75–86) who received first-line Nivo-Ipi therapy from December 2020 to November 2022 at four institutes in Japan. Patient characteristics, therapeutic efficacy, and the incidence and severity of adverse events (AE) were assessed. …”
Get full text
Article -
422
-
423
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
Published 2025-02-01Get full text
Article -
424
-
425
Long-term outcomes of robot-assisted versus minimally invasive esophagectomy in patients with thoracic esophageal cancer: a propensity score-matched study
Published 2024-03-01“…However, there are no reports on the long-term outcomes of RAMIE in Japan. This study compared the long-term outcomes of RAMIE and MIE. …”
Get full text
Article -
426
Placental malaria infection is associated with downregulation of STAT-6 and ANG-1 in decidual macrophages
Published 2025-02-01Get full text
Article -
427
Global decadal measurements of methanol, ethene, ethyne, and HCN from the Cross-track Infrared Sounder
Published 2025-02-01Get full text
Article -
428
Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment incl...
Published 2025-02-01“…Methods The PADDLE trial, which is sponsored by Ono Pharmaceutical, is an investigator-initiated, multicenter, open-label, single-arm, prospective phase II trial conducted at six institutions in Japan. Key eligibility criteria are as follows: (1) advanced gastric or esophagogastric junction cancer, (2) histologically confirmed diagnosis of adenocarcinoma, (3) refractory to first-line treatment including fluoropyrimidines, platinum, and an anti-PD-1/PD-L1 antibody, (4) performance status of 0–1, and (5) at least one measurable lesion. …”
Get full text
Article -
429
-
430
Older adults’ Internet use behavior and its association with accelerometer-derived physical activity
Published 2025-02-01Get full text
Article -
431
-
432
-
433
Detection Rate of Helicobacter Pylori Infection and Atrophic Gastritis Using Serological Markers “GastroPanel®” Among Employees of the National Medical Research Radiological Centre...
Published 2024-05-01“…Esophagogastroduodenoscopy (EGDS) for suspected atrophic gastritis was performed with an Olympus GIF-HQ190 video endoscope (Japan) in a narrow-spectrum mode with close focus (NBI Dual Focus).Results. …”
Get full text
Article -
434
-
435
MO-GCN: A multi-omics graph convolutional network for discriminative analysis of schizophrenia
Published 2025-02-01Get full text
Article -
436
A Candidate High-velocity Exoplanet System in the Galactic Bulge
Published 2025-01-01Get full text
Article -
437
-
438
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
Published 2023-06-01“…Objectives In this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients.Methods We conducted a retrospective multicentre study in referral centres from France, Italy, Spain, Armenia, Israel, Japan, Tunisia and Russia regarding biological-targeted therapies in TAK, since January 2017 to September 2019.Results A total of 109 TAK patients received at least 3 months tocilizumab therapy and were included in this study. …”
Get full text
Article -
439